METFORMIN VERSUS CLOMIPHENE CITRATE FOR OVULATION INDUCTION IN POLYCYSTIC OVARY SYNDROME: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.56238/levv17n56-047Keywords:
Polycystic Ovary Syndrome, Metformin, Clomiphene Citrate, Ovulation InductionAbstract
Introduction: Polycystic ovary syndrome is one of the most common causes of anovulatory infertility worldwide and represents a major clinical challenge in reproductive endocrinology. Pharmacological ovulation induction remains the cornerstone of treatment for women with this condition who desire pregnancy, with clomiphene citrate and metformin being among the most frequently prescribed agents. Despite decades of clinical use, uncertainty persists regarding the comparative effectiveness and safety of these drugs, particularly in different phenotypic presentations of the syndrome and in contemporary clinical practice.
Objective: The main objective of this systematic review was to compare the efficacy of metformin versus clomiphene citrate for ovulation induction in women with polycystic ovary syndrome. Secondary objectives were to evaluate differences in ovulation rates, clinical pregnancy rates, live birth rates, adverse effects, and treatment tolerability between the two interventions.
Methods: A systematic search was conducted in PubMed, Scopus, Web of Science, Cochrane Library, LILACS, ClinicalTrials.gov, and the International Clinical Trials Registry Platform. Randomized and non-randomized clinical studies comparing metformin and clomiphene citrate for ovulation induction in women with polycystic ovary syndrome were eligible. Study selection, data extraction, and risk of bias assessment were performed independently by two reviewers, with qualitative synthesis of outcomes.
Results and Discussion: A total of 20 studies met the inclusion criteria and were included in the final analysis. Overall, clomiphene citrate demonstrated higher ovulation and pregnancy rates in the general polycystic ovary syndrome population, whereas metformin showed potential benefits in specific subgroups, particularly women with insulin resistance or obesity. Combined or sequential use of both agents was frequently associated with improved reproductive outcomes, although heterogeneity across studies and variable methodological quality limited definitive conclusions.
Conclusion: Current evidence suggests that clomiphene citrate remains the first-line pharmacological agent for ovulation induction in most women with polycystic ovary syndrome, while metformin may play a complementary role in selected patients. Individualized treatment strategies based on metabolic profile and reproductive goals are essential to optimize clinical outcomes.
Downloads
References
1 Chen, X., Liu, Y., Zhang, L., et al. (2023). Comparative reproductive outcomes of metformin and clomiphene citrate in polycystic ovary syndrome. BMC Endocrine Disorders, 23(1), Article 112.
2 Chen, Z. J., Shi, Y., Sun, Y., et al. (2022). Ovulation induction strategies for polycystic ovary syndrome: Recent advances. The Lancet Diabetes & Endocrinology, 10(4), 273–285.
3 Gao, L., Wang, Y., Li, Y., et al. (2021). Comparative effectiveness of ovulation induction therapies in polycystic ovary syndrome. Frontiers in Endocrinology, 12, Article 640111.
4 Huang, H., Xu, Y., Wu, X., et al. (2023). Live birth outcomes following pharmacological ovulation induction in polycystic ovary syndrome. Fertility and Sterility, 120(1), 123–131.
5 Huang, R., Chen, Y., Luo, X., et al. (2024). Phenotype-based treatment of infertility in polycystic ovary syndrome. Reproductive Biology and Endocrinology, 22(1), Article 34.
6 Huang, Y., Wang, Y., Zhang, J., et al. (2022). Combination therapy for ovulation induction in polycystic ovary syndrome. Reproductive Sciences, 29(9), 2603–2612.
7 Kim, J. H., Lee, J. E., Kim, S. H., et al. (2022). Real-world effectiveness of ovulation induction therapies in polycystic ovary syndrome. Clinical Endocrinology, 97(5), 654–662.
8 Kim, Y. S., Park, H. J., Lee, J. R., et al. (2024). Contemporary trends in ovulation induction for polycystic ovary syndrome. Journal of Clinical Medicine, 13(2), Article 421.
9 Legro, R. S., Arslanian, S. A., Ehrmann, D. A., et al. (2020). Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 105(9), e3369–e3406.
10 Li, X., Yu, Y., Zhang, X., et al. (2021). Ovulation induction outcomes of clomiphene citrate versus metformin in women with polycystic ovary syndrome. Reproductive Biomedicine Online, 42(3), 583–592.
11 Liang, S., He, Y., Xu, Y., et al. (2021). Insulin resistance modifies response to ovulation induction in polycystic ovary syndrome. Clinical Endocrinology, 95(2), 291–299.
12 Morley, L. C., Tang, T., Yasmin, E., et al. (2020). Metformin versus clomiphene citrate in polycystic ovary syndrome: A Cochrane review. Cochrane Database of Systematic Reviews, 12, Article CD003053.
13 Morotti, E., Battaglia, B., Fabbri, R., et al. (2023). Metabolic predictors of ovulation induction success in polycystic ovary syndrome. Endocrine, 82(1), 123–131.
14 Palomba, S., Costello, M. F., & Teede, H. J. (2022). Treatment of infertility in polycystic ovary syndrome. Nature Reviews Endocrinology, 18(4), 204–216.
15 Palomba, S., Costello, M. F., & Teede, H. J. (2024). Precision medicine in polycystic ovary syndrome–related infertility. Fertility and Sterility, 121(3), 567–576.
16 Palomba, S., de Wilde, M. A., Falbo, A., et al. (2021). Pregnancy complications in women with polycystic ovary syndrome. Human Reproduction Update, 27(2), 223–245.
17 Palomba, S., Falbo, A., & La Sala, G. B. (2020). Effects of metformin in women with polycystic ovary syndrome: A systematic review and meta-analysis. Fertility and Sterility, 114(4), 799–815.
18 Palomba, S., Santagni, S., Falbo, A., et al. (2021). Complications and challenges associated with polycystic ovary syndrome. Fertility and Sterility, 115(3), 614–623.
19 Singh, M., Ahuja, M., Goyal, L. D., et al. (2023). Ovulation induction outcomes in South Asian women with polycystic ovary syndrome. International Journal of Gynecology & Obstetrics, 160(2), 456–463.
20 Teede, H. J., Joham, A. E., Paul, E., et al. (2021). Long-term cardiometabolic consequences of polycystic ovary syndrome. Nature Reviews Endocrinology, 17(11), 635–650.
21 Teede, H. J., Misso, M. L., Costello, M. F., et al. (2020). International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 35(8), 1602–1618.
22 Teede, H. J., Tay, C. T., Laven, J. S. E., et al. (2023). Polycystic ovary syndrome: New insights into pathophysiology and management. The Lancet, 402(10397), 1493–1506.
23 Wang, J., Zhu, Q., Zhang, S., et al. (2023). Safety and tolerability of metformin versus clomiphene citrate in ovulation induction. Gynecological Endocrinology, 39(7), 601–607.
24 Wang, R., Li, W., Bordewijk, E. M., et al. (2020). First-line ovulation induction for polycystic ovary syndrome: A systematic review and network meta-analysis. Human Reproduction Update, 26(2), 281–304.
25 Zeng, X. L., Zhang, Y., Tian, Q., et al. (2021). Metformin versus clomiphene citrate for ovulation induction in polycystic ovary syndrome: Updated evidence. Gynecological Endocrinology, 37(6), 493–499.
26 Zhao, H., Li, Y., Sun, X., et al. (2024). Personalized ovulation induction strategies in polycystic ovary syndrome. Frontiers in Endocrinology, 15, Article 1298743.
27 Zhao, J., Zhang, Q., Li, Y., et al. (2022). Metformin versus clomiphene citrate in overweight women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research, 48(3), 612–620.
